We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharma and Twilio highlighted as Zacks Bull and Bear of the Day
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 6, 2021 – Zacks Equity Research Shares of Vertex Pharmaceuticals Incorporated (VRTX - Free Report) as the Bull of the Day, Twilio Inc. (TWLO - Free Report) as the Bear of the Day.
Vertex Pharmaceuticals is the $52 billion hero of tens of thousands of families facing the cruel childhood disease of cystic fibrosis.
Cystic fibrosis (CF) is an inherited disorder of the body's mucus glands that causes severe damage to the lungs, digestive system and other organs in the body. CF affects the cells that produce mucus, sweat and digestive juices.
These secreted fluids are normally thin and slippery, but CF causes these fluids to become thick and sticky. They then plug up tubes, ducts, and passageways, often causing repeated lung infections.
CF is a chronic, progressive, and frequently fatal genetic diseased caused when a child has inherited two copies of the defective CF gene, one copy from each parent. Both parents must have at least one copy of the defective gene. People with only one copy of the defective CF gene are called carriers, but they do not have the disease.
Diving Deeper to Understand the Genetic Roots
Before we learn more about Vertex and its treatments, I want to share more interesting background on the science surrounding CF.
I became more interested in the disease when I read about the work of scientists in Carl Zimmer's 2008 book Microcosm. Zimmer told the story of research into the capability of animal bodies to be their own natural pharmacy by creating antimicrobial peptides, which are part of the innate immune system including skin and the linings of our respiratory and digestive systems.
During the COVID-19 pandemic, we are all learning about the acquired, or adaptive, immune system as vaccines can teach our body's interior and circulatory cells to fight viral infection. But we take for granted the front-lines of defense in our respiratory and digestive linings, whose soldiers include mucus-generating cells to protect us with natural barriers that can trap bacteria and viruses.
CF patients can never take their innate immune system barriers for granted. In Zimmer's book, he hypothesized at the time that CF may be due in part to mutations that disable genes for antimicrobial peptides produced in the lungs. But what actually causes the lungs to become loaded with bacteria and swell with fluid?
Scientists now know that CF is caused by many possible mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. There are around 2,000 identified mutations in the gene, and 127 of these are currently known to cause CF.
If the CFTR gene has a defect, it can create CFTR proteins within cells that don’t open correctly or don’t get to the cell surface, where they are normally positioned, to let chloride ions flow freely into or out of the cells as they should. This leads to an imbalance of salt and water and this causes the thick, sticky mucus in the lungs.
You can think of the CFTR protein as a channel on the surface of a mucus cell that allows chloride ions to flow in and out. Scientists believe that gateways on either end of the protein channel don't open properly or stay open long enough to effectively let chloride ions have passage.
CF lung disease eventually worsens to the point where the person is disabled. Today, the average life span for people with CF who live to adulthood is about 44 years. Death is most often caused by lung complications and many can die in their 20s.
Vertex Leads with CF Treatment
While there is no cure yet for this genetic disease, Vertex has several drug treatments approved by the FDA for daily use that help the CFTR protein gates and channels to stay open longer and allow the passage of chloride ions. Since there are multiple CFTR mutations that cause CF, the company has developed a unique arsenal of treatments for a handful of them across different ages of patients and disease progression.
In 2012, Vertex gained FDA approval of the first drug, Kalydeco, to treat the underlying cause of cystic fibrosis rather than the symptoms, in patients 6 years or older who have the G551D gene mutation. Since then, the scientific innovation has been powerful for CF patients and their families.
The company’s lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat around half of the 83,000 people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation.
Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. Trikafta is also being evaluated in younger patients in the United States. With approval of Trikafta/Kaftrio, Vertex can address a significantly larger CF patient population -- almost 90% of patients with CF -- in the future.
While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease and beta-thalassemia with its partner CRISPR Therapeutics.
Vertex is projected to grow revenues this year to $7.25 billion, representing a 17% advance. And next year's consensus among analysts is nearly $8 billion for a 10% rise.
After its July 29 quarterly report where the company offered an improved outlook for sales and profits, analysts have raised EPS estimates significantly, thus making Vertex a Zacks #1 Rank. In just the past week, this year's EPS consensus rose 9.5% $12.28, representing 19% profit growth.
Second Quarter Details
Vertex reported Q2 adjusted diluted EPS of $3.11, up from $2.61 a year ago, beating the Zacks consensus of $2.69 by 15.6%.
Revenues of $1.79 billion grew 17.8% from the year-ago quarter and also surpassed the Zacks Consensus Estimate of $1.71 billions, primarily driven by the rapid uptake of Trikafta in Europe (marketed as Kaftrio) and continued growth in the United States. Product revenues rose 4% year over year to $1.26 billion in the United States and surged 71% to $536 million outside the country.
The biopharmaceutical firm raised its full-year 2021 product revenue guidance to a range of $7.2 billion to $7.4 billion from $6.7 billion to $6.9 billion, versus the Street view of $6.99 billion.
CF Franchise Sales Performance
Vertex’s newest drug, Trikafta, a triple combination therapy, generated sales worth $1.26 billion, up 36.8% year over year, driven by high level of treatment penetration in the United States as well as strong launches in international markets.
In June 2021, the FDA approved Trikafta to treat CF in children aged six to 11 years who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on in vitro data.
Kaftrio was approved in Europe in August 2020. Following the nod, the drug saw substantial uptake across all European countries. The company has now secured reimbursement agreements in more than 15 countries, most importantly the large markets of Germany and the United Kingdom.
Symdeko/Symkevi registered sales of $134 million in the quarter, down 22.1% year over year.
Kalydeco recorded sales of $183 million in the quarter, reflecting a 9.8% decrease year over year. Orkambi generated sales of $221 million in the reported quarter, down 4.7%. Sales of Kalydeco, Symdeko/Symkevi and Orkambi were hurt by patients switching to Trikafta.
Analyst Reactions and Price Targets
Oppenheimer: After reviewing the company pipeline update and outlook, the analyst team noted that Vertex continues to demonstrate persistent strength in its CF business with high-teens growth in sales and earnings. They also admired the company's indicated timeline for phase 3 initiation of a follow-up triplet CF medication to Trikafta, that should occur in the second half of 2021. They believe that if the new combo has a better profile (safety and efficacy) than Trikafta, it could push CF competition into the next decade. Further, the company also plans pipeline updates to APOL-1 kidney disease in 2H21 and a host of catalysts in 2022. The Oppenheimer team said "We stay bullish" and they reiterated their $305 price target on the stock.
Piper Sandler: Analyst Edward Tenthoff raised the firm's price target on Vertex Pharmaceuticals to $323 from $261 and reiterated an Overweight rating on the shares. Tenthoff noted that "Trikafta beats again" in Q2 and the company maintained raised guidance. He's looking forward to multiple data readouts from the Vertex pipeline. Worth noting is that Tenthoff was the big bull on Moderna for the past year and defeating all nay-sayers, the stock has launched from $200 to $400 in the past six weeks. While we made some good trades in MRNA, I sure wish I would have listened to Ed a little closer about the potential. He's a veteran biotech analyst who has followed and met with many complex companies over the years and I highly respect his research.
SVB Leerink: This respected lifesciences research firm remains bearish on VRTX, with an Underperform rating and $175 PT. They are concerned that the CF franchise will plateau soon and that promising new medicines from the pipeline may be further distant. The most important pipeline events are likely to be the proof-of-concept (POC) results in APOL-1-mediated kidney disease (2H21) and POC results in acute pain (early 2022). The Leerink team writes "We continue to believe that Vertex’s large CF franchise and substantial market cap will require more shots on goal than the current pipeline offers, and with substantial capital reserves, we expect increasing business development activity from the company to broaden the clinical development portfolio."
As I've learned more about Vertex and how they took on a disease, CF -- that few thought they could treat -- I am excited to be a shareholder at these levels for what might unfold if their scientists can create another winning family of treatments. The next 6-12 months could give you better opportunities to buy the stock under $200, but I see the reward-to-risk as skewed heavily in favor of the upside by a factor of 4-to-1.
Disclosure: I own shares of VRTX and CRSP for the Zacks Healthcare Innovators portfolio.
I last wrote about Twilio, the $65 billion enterprise software communications platform, in May as their earnings outlook had taken a turn down. Here's what I observed...
While analyst EPS estimates kept dropping in March, they just took another turn south after the company's Q2 report on May 5.
And that quarterly update was digested with a stock price plunge from $335 to $275 by the second week of May.
In just the past two weeks since the company report, the analyst consensus for TWLO EPS growth for 2021 has dropped from a loss of 13-cents per share to -19 cents.
That represents a turn of fortune from profitability in 2020 to a minus 180% annual loss.
As I wrote in Feb, "While average analyst price targets moved up to north of $500, the stock is probably due for a pause as earnings momentum decelerates."
So where are we now? TWLO remains a powerful player in a small-but-growing niche and their projected 43% revenue growth to top $2.5 billion this year verifies this.
Buying under $300 for the long term would seem to make some sense as it still trades under 20X next year's projected topline of $3.25 billion, representing 30% growth.
(end of May 26 article excerpt)
Twilio continues to be a cloud darling for intelligent corporate comms, with a bright future, but a temporary-turned-persistent squall on EPS growth. The latter is what puts TWLO into the cellar of the Zacks Rank, regardless of sales growth, regardless of how much they are making key investments for their future.
After their July 29 Q2 report, the analyst EPS consensus for this year got slashed from -18 cents to -28 cents, representing a 222% annual decline.
Total revenues increased a whopping 67% year over year to $668.9 million and surpassed the consensus mark of $597.7 million. Twilio's newly acquired Segment business contributed $46.6 million to the company’s total revenues. The acquisition of ValueFirst also acted as a tailwind.
Twilio is benefiting from the constant expansion of its international business as well as the continuous acceleration of digital transformation projects across many industries. In the quarter under review, the company experienced new customer growth with a strong net expansion rate.
The top-line growth was primarily driven by enhancement of customer experiences across various product portfolios like SendGrid, Segment and Flex which are its fastest-growing SaaS products at present.
Quarterly Details
Twilio's dollar-based net expansion rate was 135% in the reported quarter, up from the 133% recorded in the previous quarter and 132% in the year-ago quarter.
Twilio's active customer accounts increased to more than 240,000 as of Jun 30, 2021, from 235,000 at the end of first-quarter 2021 and 200,000 at the end of second-quarter 2020. In the second quarter, Twilio Segment customer accounts were also included in the active customer accounts.
Based on this momentum, analysts have kept topline growth in prime view with $2.66 billion projected for this year, representing 51% growth, while 2022 targets $3.44 billion, for a 29% advance.
Large investors who love the company and its long-term growth outlook may still be cautious here with the persistent EPS erosion and a Price/Sales valuation still near 20 times.
But what I said in May turned about to be stellar advice: "Buying under $300 for the long term would seem to make some sense as it still trades under 20X next year's projected topline of $3.25 billion, representing 30% growth."
I would update my guide here to "Buy near $350" if you get the chance. And don't hurry as we need to see the EPS estimates stop going down and start heading back up.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharma and Twilio highlighted as Zacks Bull and Bear of the Day
For Immediate Release
Chicago, IL – August 6, 2021 – Zacks Equity Research Shares of Vertex Pharmaceuticals Incorporated (VRTX - Free Report) as the Bull of the Day, Twilio Inc. (TWLO - Free Report) as the Bear of the Day.
Here is a synopsis of all two stocks:
Bull of the Day:
Vertex Pharmaceuticals is the $52 billion hero of tens of thousands of families facing the cruel childhood disease of cystic fibrosis.
Cystic fibrosis (CF) is an inherited disorder of the body's mucus glands that causes severe damage to the lungs, digestive system and other organs in the body. CF affects the cells that produce mucus, sweat and digestive juices.
These secreted fluids are normally thin and slippery, but CF causes these fluids to become thick and sticky. They then plug up tubes, ducts, and passageways, often causing repeated lung infections.
CF is a chronic, progressive, and frequently fatal genetic diseased caused when a child has inherited two copies of the defective CF gene, one copy from each parent. Both parents must have at least one copy of the defective gene. People with only one copy of the defective CF gene are called carriers, but they do not have the disease.
Diving Deeper to Understand the Genetic Roots
Before we learn more about Vertex and its treatments, I want to share more interesting background on the science surrounding CF.
I became more interested in the disease when I read about the work of scientists in Carl Zimmer's 2008 book Microcosm. Zimmer told the story of research into the capability of animal bodies to be their own natural pharmacy by creating antimicrobial peptides, which are part of the innate immune system including skin and the linings of our respiratory and digestive systems.
During the COVID-19 pandemic, we are all learning about the acquired, or adaptive, immune system as vaccines can teach our body's interior and circulatory cells to fight viral infection. But we take for granted the front-lines of defense in our respiratory and digestive linings, whose soldiers include mucus-generating cells to protect us with natural barriers that can trap bacteria and viruses.
CF patients can never take their innate immune system barriers for granted. In Zimmer's book, he hypothesized at the time that CF may be due in part to mutations that disable genes for antimicrobial peptides produced in the lungs. But what actually causes the lungs to become loaded with bacteria and swell with fluid?
Scientists now know that CF is caused by many possible mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. There are around 2,000 identified mutations in the gene, and 127 of these are currently known to cause CF.
If the CFTR gene has a defect, it can create CFTR proteins within cells that don’t open correctly or don’t get to the cell surface, where they are normally positioned, to let chloride ions flow freely into or out of the cells as they should. This leads to an imbalance of salt and water and this causes the thick, sticky mucus in the lungs.
You can think of the CFTR protein as a channel on the surface of a mucus cell that allows chloride ions to flow in and out. Scientists believe that gateways on either end of the protein channel don't open properly or stay open long enough to effectively let chloride ions have passage.
CF lung disease eventually worsens to the point where the person is disabled. Today, the average life span for people with CF who live to adulthood is about 44 years. Death is most often caused by lung complications and many can die in their 20s.
Vertex Leads with CF Treatment
While there is no cure yet for this genetic disease, Vertex has several drug treatments approved by the FDA for daily use that help the CFTR protein gates and channels to stay open longer and allow the passage of chloride ions. Since there are multiple CFTR mutations that cause CF, the company has developed a unique arsenal of treatments for a handful of them across different ages of patients and disease progression.
In 2012, Vertex gained FDA approval of the first drug, Kalydeco, to treat the underlying cause of cystic fibrosis rather than the symptoms, in patients 6 years or older who have the G551D gene mutation. Since then, the scientific innovation has been powerful for CF patients and their families.
The company’s lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat around half of the 83,000 people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation.
Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. Trikafta is also being evaluated in younger patients in the United States. With approval of Trikafta/Kaftrio, Vertex can address a significantly larger CF patient population -- almost 90% of patients with CF -- in the future.
While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease and beta-thalassemia with its partner CRISPR Therapeutics.
Vertex is projected to grow revenues this year to $7.25 billion, representing a 17% advance. And next year's consensus among analysts is nearly $8 billion for a 10% rise.
After its July 29 quarterly report where the company offered an improved outlook for sales and profits, analysts have raised EPS estimates significantly, thus making Vertex a Zacks #1 Rank. In just the past week, this year's EPS consensus rose 9.5% $12.28, representing 19% profit growth.
Second Quarter Details
Vertex reported Q2 adjusted diluted EPS of $3.11, up from $2.61 a year ago, beating the Zacks consensus of $2.69 by 15.6%.
Revenues of $1.79 billion grew 17.8% from the year-ago quarter and also surpassed the Zacks Consensus Estimate of $1.71 billions, primarily driven by the rapid uptake of Trikafta in Europe (marketed as Kaftrio) and continued growth in the United States. Product revenues rose 4% year over year to $1.26 billion in the United States and surged 71% to $536 million outside the country.
The biopharmaceutical firm raised its full-year 2021 product revenue guidance to a range of $7.2 billion to $7.4 billion from $6.7 billion to $6.9 billion, versus the Street view of $6.99 billion.
CF Franchise Sales Performance
Vertex’s newest drug, Trikafta, a triple combination therapy, generated sales worth $1.26 billion, up 36.8% year over year, driven by high level of treatment penetration in the United States as well as strong launches in international markets.
In June 2021, the FDA approved Trikafta to treat CF in children aged six to 11 years who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on in vitro data.
Kaftrio was approved in Europe in August 2020. Following the nod, the drug saw substantial uptake across all European countries. The company has now secured reimbursement agreements in more than 15 countries, most importantly the large markets of Germany and the United Kingdom.
Symdeko/Symkevi registered sales of $134 million in the quarter, down 22.1% year over year.
Kalydeco recorded sales of $183 million in the quarter, reflecting a 9.8% decrease year over year. Orkambi generated sales of $221 million in the reported quarter, down 4.7%. Sales of Kalydeco, Symdeko/Symkevi and Orkambi were hurt by patients switching to Trikafta.
Analyst Reactions and Price Targets
Oppenheimer: After reviewing the company pipeline update and outlook, the analyst team noted that Vertex continues to demonstrate persistent strength in its CF business with high-teens growth in sales and earnings. They also admired the company's indicated timeline for phase 3 initiation of a follow-up triplet CF medication to Trikafta, that should occur in the second half of 2021. They believe that if the new combo has a better profile (safety and efficacy) than Trikafta, it could push CF competition into the next decade. Further, the company also plans pipeline updates to APOL-1 kidney disease in 2H21 and a host of catalysts in 2022. The Oppenheimer team said "We stay bullish" and they reiterated their $305 price target on the stock.
Piper Sandler: Analyst Edward Tenthoff raised the firm's price target on Vertex Pharmaceuticals to $323 from $261 and reiterated an Overweight rating on the shares. Tenthoff noted that "Trikafta beats again" in Q2 and the company maintained raised guidance. He's looking forward to multiple data readouts from the Vertex pipeline. Worth noting is that Tenthoff was the big bull on Moderna for the past year and defeating all nay-sayers, the stock has launched from $200 to $400 in the past six weeks. While we made some good trades in MRNA, I sure wish I would have listened to Ed a little closer about the potential. He's a veteran biotech analyst who has followed and met with many complex companies over the years and I highly respect his research.
SVB Leerink: This respected lifesciences research firm remains bearish on VRTX, with an Underperform rating and $175 PT. They are concerned that the CF franchise will plateau soon and that promising new medicines from the pipeline may be further distant. The most important pipeline events are likely to be the proof-of-concept (POC) results in APOL-1-mediated kidney disease (2H21) and POC results in acute pain (early 2022). The Leerink team writes "We continue to believe that Vertex’s large CF franchise and substantial market cap will require more shots on goal than the current pipeline offers, and with substantial capital reserves, we expect increasing business development activity from the company to broaden the clinical development portfolio."
As I've learned more about Vertex and how they took on a disease, CF -- that few thought they could treat -- I am excited to be a shareholder at these levels for what might unfold if their scientists can create another winning family of treatments. The next 6-12 months could give you better opportunities to buy the stock under $200, but I see the reward-to-risk as skewed heavily in favor of the upside by a factor of 4-to-1.
Disclosure: I own shares of VRTX and CRSP for the Zacks Healthcare Innovators portfolio.
Bear of the Day:
I last wrote about Twilio, the $65 billion enterprise software communications platform, in May as their earnings outlook had taken a turn down. Here's what I observed...
While analyst EPS estimates kept dropping in March, they just took another turn south after the company's Q2 report on May 5.
And that quarterly update was digested with a stock price plunge from $335 to $275 by the second week of May.
In just the past two weeks since the company report, the analyst consensus for TWLO EPS growth for 2021 has dropped from a loss of 13-cents per share to -19 cents.
That represents a turn of fortune from profitability in 2020 to a minus 180% annual loss.
As I wrote in Feb, "While average analyst price targets moved up to north of $500, the stock is probably due for a pause as earnings momentum decelerates."
So where are we now? TWLO remains a powerful player in a small-but-growing niche and their projected 43% revenue growth to top $2.5 billion this year verifies this.
Buying under $300 for the long term would seem to make some sense as it still trades under 20X next year's projected topline of $3.25 billion, representing 30% growth.
(end of May 26 article excerpt)
Twilio continues to be a cloud darling for intelligent corporate comms, with a bright future, but a temporary-turned-persistent squall on EPS growth. The latter is what puts TWLO into the cellar of the Zacks Rank, regardless of sales growth, regardless of how much they are making key investments for their future.
After their July 29 Q2 report, the analyst EPS consensus for this year got slashed from -18 cents to -28 cents, representing a 222% annual decline.
Total revenues increased a whopping 67% year over year to $668.9 million and surpassed the consensus mark of $597.7 million. Twilio's newly acquired Segment business contributed $46.6 million to the company’s total revenues. The acquisition of ValueFirst also acted as a tailwind.
Twilio is benefiting from the constant expansion of its international business as well as the continuous acceleration of digital transformation projects across many industries. In the quarter under review, the company experienced new customer growth with a strong net expansion rate.
The top-line growth was primarily driven by enhancement of customer experiences across various product portfolios like SendGrid, Segment and Flex which are its fastest-growing SaaS products at present.
Quarterly Details
Twilio's dollar-based net expansion rate was 135% in the reported quarter, up from the 133% recorded in the previous quarter and 132% in the year-ago quarter.
Twilio's active customer accounts increased to more than 240,000 as of Jun 30, 2021, from 235,000 at the end of first-quarter 2021 and 200,000 at the end of second-quarter 2020. In the second quarter, Twilio Segment customer accounts were also included in the active customer accounts.
Based on this momentum, analysts have kept topline growth in prime view with $2.66 billion projected for this year, representing 51% growth, while 2022 targets $3.44 billion, for a 29% advance.
Large investors who love the company and its long-term growth outlook may still be cautious here with the persistent EPS erosion and a Price/Sales valuation still near 20 times.
But what I said in May turned about to be stellar advice: "Buying under $300 for the long term would seem to make some sense as it still trades under 20X next year's projected topline of $3.25 billion, representing 30% growth."
I would update my guide here to "Buy near $350" if you get the chance. And don't hurry as we need to see the EPS estimates stop going down and start heading back up.
The Zacks Rank will let you know.
For other stocks growing fat double-digit sales, and actual profits, check out my recent vlog Stocks in My Hood: AMD, SQ, NVDA.
Disclosure: I own AMD, SQ, and NVDA for the Zacks TAZR portfolio.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.